(mean age: 63±10 years [range 49-73]) and 10 patients not receiving HOT (mean age: 66±10 years [range 42-78]). The study protocol, including a randomized control study, was approved by the institutional ethics review broad and written informed consent was given by all patients prior to entry.
Study Protocol
All patients in the HOT group received overnight nasal 3 L/min oxygen (O2) every night for 3 months. 8 We performed a series of examinations including polysomnography (PG), cardiopulmonary exercise testing (CPET), 123 I-MIBG imaging and 99m Tc-MIBI imaging within the 2 weeks before and after 3 months of this study. At the same time, we estimated cardiac symptoms based on NYHA functional class and exercise capacity using the Specific Activity Scale (SAS). In the HOT group, PG performed after 3 months was while patients were receiving the O2 therapy.
PG Patients underwent overnight PG using a computerized system (CompuMedic E-Series Sleep System; CompuMEdic; Abbotsford, Vic., Australia). With this system, the electroencephalogram, electrooculogram, electromyogram, and electrocardiogram are recorded and analyzed automatically. Air flow from the nose or mouth is recorded with a thermister, and thoracic and abdominal wall motion monitored with plethysmography. Arterial oxygen saturation (SaO2%) was measured transcutaneously by pulse oximetry. Hypopnea was defined as a fall in oronasal air flow >50% of baseline for more than 10 s associated with a decrease in SaO2% >3%. Apnea was defined as the absence of oronasal air flow for the same period. The number of episodes of apnea and hypopnea per hour was defined as the apnea-hypopnea index (AHI). AHI >5 times/h was considered to indicate significant sleep apnea syndrome. An episode of obstructive apnea was defined as the absence of airflow in the presence of rib-cage and abdominal excursion. An episode of central apnea was defined as the absence of both airflow and rib-cage and abdominal motion.
Functional Capacity Functional capacity was scored as the NYHA class and by the SAS, which asked all patients 21 questions at the beginning and after 3 months of this study. 9, 10 Cardiopulmonary Exercise Test All patients underwent symptom-limited CPET in the upright position on a calibrated cycle ergometer (CPE2000, MedGraphics, St Paul, MN, USA). Exercise was started with 4 min of warm-up at 20 W, followed by a continuous increase in workload until termination when the patient complained of exhaustion. We estimated exercise tolerance from the oxygen uptake at the anaerobic threshold (AT V • O2) and peak oxygen uptake (peak V • O2). 11 123 I-MIBG and 99m Tc-MIBI Imaging The 123 I-MIBG and 99m Tc-sestamibi (MIBI) isotopes were obtained commercially (Daiichi Radioisotope Laboratories, Chiba, Japan). All medicines, including β-blockers, were withheld on the day of the 123 I-MIBG and 99m Tc-MIBI studies. Patients were injected intravenously with 111 Mbq of 123 I-MIBG while upright and 15 min later anterior planar and SPECT was performed and repeated after 4 h. Immediately after 123 I-MIBG image acquisition, the patients were injected with 720 MBq of 99m Tc-MIBI while upright and then imaged 30 min later.
Using the anterior planar delayed 123 I-MIBG images, the heart-to-mediastinum (H/M) activity ratio was obtained using regions of interest positioned over the heart and upper mediastinum. The washout rate (WR) was calculated as: (H/M) early -(H/M) delayed / (H/M) early × 100. 12, 13 The myocardial SPECT image set for each patient was divided into 20 segments. The short-axis images at the basal, middle, and apical ventricular levels were divided into 6 segments each. The apical segment of the vertical long-axis image was divided into 2 segments. Regional tracer uptake was scored semiquantitatively using a 4-point scoring system (0= normal uptake; 1= mildly reduced uptake; 2= moderately reduced uptake; 3= severely reduced uptake). The total defect score (TDS) was calculated as the sum of the scores for all 20 segments.
Commercially available QGS software (Cedars-Sinai Medical Center, Los Angeles, CA, USA) with a temporal resolution of 16 frames/RR interval was used to create a 3-dimensional surface cinemode display, which was used to calculate the LVEF, LV end-diastolic and end-systolic volumes (LVEDV, LVESV) throughout the cardiac cycle using an automatic edge detection algorithm. 14 
Statistical Analysis
Statistical analysis was performed with STATVIEW (SAS Institute Inc, Cary, NC, USA) on a Macintosh computer. Specific comparisons of parameters were performed using paired 2-tailed t-tests. Unpaired 2-tailed t-tests were used to make comparisons between 2 groups. All values are expressed as the mean ± SD. Significant differences were defined by P<0.05.
Results

AHI and the Change in AHI
At baseline, the AHI was comparable between the 2 groups, but after 3 months of HOT (5.1±3.4), it had decreased significantly from the baseline value (26.1±9.1, P<0.01), and was unchanged in the non-HOT group ( Table 2 ). The HOT was well tolerated for 3 months with no adverse effects. A representative case is shown in Fig 1. 
NYHA Functional Class
At baseline, the NYHA functional class and SAS data were comparable between groups (Table 1) . After 3 months of HOT treatment, the NYHA functional class had improved while remaining unchanged in the non-HOT group. Similarly, the SAS improved from the baseline value in the HOT group (4.0±0.9 Mets to 5.8±1.2 Mets, P<0.01), but 
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was unchanged in the non-HOT group.
AT V • O2 and Peak V • O2
The baseline AT V
• O2 and peak V • O2 values were comparable between the HOT and non-HOT groups (Table 3) . At 3 months, the AT V
• O2 was unchanged in each group, whereas the peak V
• O2 had improved significantly from 16.0±3.8 to 18.3±4.7 ml · min -1 · kg -1 in the HOT group (P<0.05), while remaining unchanged in the non-HOT group. Moreover the difference in the peak V
• O2 of the HOT group (2.3± 2.5 ml · min -1 · kg -1 ) was significantly greater than the non-HOT group (-0.3±2.0 ml · min -1 · kg -1 , P=0.02).
LVEDV, LVESV and LVEF on the QGS Images
The baseline LVEDV, LVESV and LVEF values were comparable between the HOT and non-HOT groups (Table 4) . After 3 months of HOT (37±10%), the LVEF improved significantly from the baseline value (27±9%, P<0.01), but remained unchanged in the non-HOT group. Moreover, the difference in the LVEF of the HOT group (9.7±9.1%) was significantly higher than that of non-HOT group (1.3±3.3%, P=0.013). In the HOT group, the LVEDV improved significantly from 234±70 ml to 185±58 ml (P<0.05) and the LVESV was also improved significantly from 174±71 ml to 121±56 ml (P<0.05), while remaining unchanged in the non-HOT group.
TDS and H/M Ratio on the 123 I-MIBG Images
The TDS in the HOT group improved significantly from 31±8 to 25±9 (P<0.05), while remaining unchanged in the Representative case from the home oxygen therapy (HOT) group. 123 I-metaiodobenzylguanidine (MIBG) images obtained from short-axis and vertical long-axis reconstructions. Before HOT, 123 I-MIBG uptake was decreased in the inferior to apical walls. After 3 months of HOT, uptake in the same area has improved. The heart-to-mediastinum ratio increased from 1.43 to 1.65 and the left ventricular ejection fraction increased from 16% to 29% after treatment. non-HOT group (Table 4 ). Moreover the difference in the TDS in the HOT group was significantly greater than in the non-HOT group (P=0.006). The H/M ratio in the HOT group improved significantly from 1.69±0.22 to 1.82±0.22 (P<0.05), while remaining unchanged in the non-HOT group. Figs 2 and 3 are representative cases from the HOT and non-HOT groups, respectively.
WR on the 123 I-MIBG Images
The WR in the HOT group improved significantly from 49±8% to 41±5% (P<0.05), but was unchanged in the non-HOT group and, moreover, the difference in the WR in the HOT group was significantly greater than in the non-HOT group (P=0.038) ( Table 4) .
TDS on the 99m Tc-MIBI Images
The TDS did not change significantly in either group (Table 4) .
Discussion
In the present study, 3 months of HOT decreased the AHI significantly in patients with CHF and CSA, whereby functional capacity, exercise tolerance, and LVEF were increased and cardiac sympathetic nerve activity was suppressed. There have been several clinical studies of HOT for CSA. Franklin et al reported oxygen therapy decreased the median number of all central AHI from 33.5 to 5/h of sleep. 15 Similarly, Andreas et al reported that the AHI fell from 26 to 10/h with HOT. 16 However, these previous studies were limited to short-term evaluation within 1 month. The present study confirmed sustained effectiveness of HOT for CSA in CHF for at least for 3 months in terms of functional capacity, cardiac function, and cardiac sympathetic nerve activity, as well as AHI.
There have been previous reports of estimating sympathetic nerve activity using plasma or urine norepinephrine concentrations in patients with CHF and CSA. Staniforth et al reported that HOT reduced the frequency of CheyneStokes respiration and reduced overnight urinary noradrenaline excretion in patients with CHF and CSA. 4 They concluded that HOT stabilized Cheyne-Stokes respiration and improved sympathetic nerve activity, but there were no differences in the daytime serum noradrenaline and adrenaline concentrations between the HOT and control groups. Moreover, overnight urinary noradrenaline excretion does not necessarily reflect cardiac sympathetic nerve activity. In our study, we estimated cardiac sympathetic nerve activity using 123 I-MIBG scintigraphy, which is an analog of noradrenaline and has been reported to provide images that reflect cardiac sympathetic function. 5,6 123 I-MIBG uptake is considered useful for the evaluation of the severity of heart failure. 6, 12 In addition, the H/M ratio, TDS and WR on 123 I-MIBG can be used to determine prognosis and evaluate therapeutic efficacy. 6, 12, 17, 18 In our study, the improvements in the TDS, H/M ratio and WR on the 123 I-MIBG images for patients receiving HOT were greater than in patients not receiving HOT. These results suggest that the improvement in CSA produced by HOT attenuated sympathetic nerve activity. Because activated sympathetic nerve activity is a poor prognostic sign in CHF, 19 an improvement in such activity can be associated with reduced mortality. 20 HOT in patients with CHF and CSA may have important implications for the treatment of CHF. There has not been a report that HOT directly improves sympathetic nerve activity in patients with CHF and CSA. From our data, HOT can improve CSA in DCM patients with CHF and CSA. The mechanism for the development of CSA is postulated to be upregulation of both central [21] [22] [23] [24] [25] and peripheral 21 chemoreceptors, which is thought to be related to elevated circulating catecholamines. 26 Mansfield et al support the theory that cardiac failure is primarily responsible for the development of CSA in CHF patients, with the increased sympathetic nerve activity and upregulated chemosensitivity being secondary. 27 HOT can also stabilize sympathetic nerve activity, which could promote improvement in cardiac symptoms and function, as well as exercise capacity, in DCM patients with CHF and CSA.
Study Limitations
First, because of the small number of patients in this study, it is difficult to sufficiently evaluate the effectiveness of HOT in patients with CHF and CSA. Second, the duration of HOT was relatively short. In the future, we need to study the long-term effects of HOT, and compare its effectiveness in a large number of patients. Representative case from the nonhome oxygen therapy (HOT) group. 123 Imetaiodobenzylguanidine (MIBG) images obtained from short-axis and vertical longaxis reconstructions. At baseline, 123 I-MIBG uptake was decreased in the inferior to apical walls and was unchanged 3 months later. Both the heart-to-mediastinum ratio and the left ventricular ejection fraction remained unchanged during the 3-month period.
